Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1456 to 1470 of 7707 results

  1. Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma (TA121)

    Evidence-based recommendations on carmustine implants (Gliadel) and temozolomide for treating newly diagnosed high-grade glioma in adults.

  2. Methadone and buprenorphine for the management of opioid dependence (TA114)

    Evidence-based recommendations on methadone and buprenorphine (oral formulations) for managing opioid dependence in adults.

  3. Naltrexone for the management of opioid dependence (TA115)

    Evidence-based recommendations on naltrexone (Nalorex) for managing opioid dependence in adults.

  4. Gemcitabine for the treatment of metastatic breast cancer (TA116)

    Evidence-based recommendations on gemcitabine for treating metastatic breast cancer in adults.

  5. Etanercept and efalizumab for the treatment of adults with psoriasis (TA103)

    Evidence-based recommendations on etanercept (Enbrel) for treating severe psoriasis in adults.

  6. Laparoscopic surgery for colorectal cancer (TA105)

    Evidence-based recommendations on laparoscopic surgery for people with colorectal cancer.

  7. Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer (TA100)

    Evidence-based recommendations on capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer in adults.

  8. Iptacopan for treating paroxysmal nocturnal haemoglobinuria (TA1000)

    Evidence-based recommendations on iptacopan (Fabhalta) for treating paroxysmal nocturnal haemoglobinuria in adults.

  9. Telbivudine for the treatment of chronic hepatitis B (TA154)

    Evidence-based recommendations on telbivudine (Sebivo) for treating chronic hepatitis B in adults.

  10. Elafibranor for previously treated primary biliary cholangitis (TA1016)

    Evidence-based recommendations on elafibranor (Iqirvo) for previously treated primary biliary cholangitis in adults.

  11. Tocilizumab for treating giant cell arteritis (TA518)

    Evidence-based recommendations on tocilizumab (RoActemra) for treating giant cell arteritis in adults.

  12. Abaloparatide for treating osteoporosis after menopause (TA991)

    Evidence-based recommendations on abaloparatide (Eladynos) for treating osteoporosis after menopause in women, trans men and non-binary people with a very high risk of fracture.

  13. Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis (terminated appraisal) (TA838)

    NICE is unable to make a recommendation on slow-release potassium bicarbonate–potassium citrate (Sibnayal) for treating distal renal tubular acidosis in people 1 year and over. This is because Advicenne withdrew its evidence submission.

    Sections for TA838

  14. Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women (TA160)

    Evidence-based recommendations on raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women.

  15. Guidance on the use of trastuzumab for the treatment of advanced breast cancer (TA34)

    Evidence-based recommendations on trastuzumab for treating advanced breast cancer in adults.